

B2 *sub Cl*  
11. (Amended) A process for producing a polypeptide [or fragment thereof] comprising culturing the transformed/transfected host cell of claim 10 under conditions sufficient for the expression of the polynucleotide of claim 23.

23. (Twice amended) An isolated or purified polynucleotide comprising a polynucleotide selected from the group consisting of:

- B3
- (a) a polynucleotide encoding the polypeptide of SEQ ID NO: 2;
  - (b) a polynucleotide of SEQ ID NO: 1;
  - (c) a polynucleotide contained in the clone deposited as National Collections of Industrial and Marine Bacteria Limited (NCIMB) 41066; and
  - (d) a polynucleotide comprising a nucleotide sequence that has at least 95% identity to the polynucleotide of any one of (a) to (c) and encodes a neuromedin U receptor.

B4  
32. (Amended) An isolated or purified polynucleotide comprising the DNA contained in the NCIMB deposit 41066.

Remarks:

1. Claims 10, 11, and 32 are amended to provide clarification. Claim 23 is also amended for clarification and to require that the polynucleotide of section (d) have at least 95% identity and encode a neuromedin U receptor. Support for the amendment to claim 23 is found in original claim 6 and in the specification at page 72, lines 26-27, and at page 74, line 9 to page 77, line 5.
2. Claims 6-12 and 22-34 stand rejected, under 35 U.S.C. § 101 and under 35 U.S.C. § 112, first paragraph, for lack of utility/enableness. In view of the current claim cancellations and amendments, Applicants request reconsideration and withdrawal of these rejections. In particular, Applicants note that the polynucleotide sequences, as now claimed, have utility as encoding neuromedin U receptors that bind neuromedin U (see specification at page 74, line 9 to page 77, line 5).